Τοποθεσία: Παρίσι, Γαλλία
Περίληψη των παρουσιάσεων
Παρουσιάσεις
Στη συνεδρίαση του 2016 έγιναν οι ακόλουθες παρουσιάσεις. Επισκεφθείτε το κανάλιECD της Παγκόσμιας Συμμαχίας στο YouTube για όλα τα δημοσιευμένα βίντεο σχετικά με το ECD.
| Presenter | Presentation Slides | Videos |
| Corrado Campochiaro, MD | Management of ECD Symptoms and Side Effects of Treatments | Management of ECD Symptoms and Side Effects of Treatments |
| Giulio Cavalli, MD | Adult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease | Adult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease |
| Carine Courtillot, MD | Endocrine manifestations in Erdheim-Chester disease | Endocrine manifestations in Erdheim-Chester disease |
| Benjamin Durham, MD | Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models | Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models |
| Marina Ferrarini, MD | Tailoring Treatment for Erdheim-Chester Disease: Focus on ECD | Tailoring Treatment for Erdheim-Chester Disease: Focus on ECD |
| Ronald Go, MD | Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD) | Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD) |
| Filip Janku, MD, PhD | Encouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease | Encouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease |
| Javier Martin, MD, PhD | Future Genetic Studies in Erdheim-Chester disease – GWAS Study | Future Genetic Studies in Erdheim-Chester disease – GWAS Study |
| Kenneth McClain, MD, PhD | Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD? | Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD? |
| Augusto Vaglio, MD, PhD | MRI evidence of cardiac involvement in Erdheim-Chester disease | MRI evidence of cardiac involvement in Erdheim-Chester disease |
